Mark Zenker, MD
Cardiovascular Disease · Nashville, TNNPI 1316985120
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,451 of the $224,932 with a category attached, or 70.0%. E.r. Squibb & Sons, L.L.C. accounts for 92.4% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $71,254, more than ten times the $6,034 reported in 2019. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $826.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$208K
- Pfizer$8K
- Alnylam Pharmaceuticals Inc.$6K
- Akcea Therapeutics, Inc.$2K
- Abbott$574
- Boston Scientific$347
- plus $980 from 11 others
Across 15 payments — averaging $51,197 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$768K
What the payments were for
- Consulting fees$30,94314%
- Speaking & faculty fees$157,45170%
- Travel & lodging$29,84913%
- Food & beverage$6,6433%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 198 | $207,865 |
| Pfizer | 17 | $7,765 |
| Alnylam Pharmaceuticals Inc. | 22 | $5,703 |
| Akcea Therapeutics, Inc. | 2 | $1,697 |
| Abbott | 6 | $574 |
| Boston Scientific | 4 | $347 |
| Novo Nordisk | 5 | $285 |
| Amgen | 3 | $156 |
| Abiomed | 1 | $130 |
| Astellas Pharma US Inc | 6 | $113 |
| Inspire Medical Systems, Inc. | 2 | $75 |
| Canon Medical Systems USA, Inc. | 1 | $68 |
| Merck | 1 | $59 |
| Bayer | 1 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| Baxter Healthcare | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$158,869
- VYNDAQEL$7,600
- ONPATTRO$5,096
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$257
- Mitra Clip system$200
- WATCHMAN Access System$173
- Impella$130
- Repatha$121
- Watchman$119
- TEGSEDI$104
How this compares
$224,932 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 49 | $1,145,102 |
| CamzyosMavacamten | 132 | $1,064,878 |
| EliquisApixaban | 348 | $361,169 |
| JardianceEmpagliflozin | 284 | $296,344 |
| EntrestoSacubitril/Valsartan | 105 | $117,101 |
| XareltoRivaroxaban | 60 | $69,866 |
| MultaqDronedarone Hcl | 24 | $38,186 |
| Repatha SureclickEvolocumab | 38 | $35,148 |
| FarxigaDapagliflozin Propanediol | 25 | $22,726 |
| VascepaIcosapent Ethyl | 40 | $17,398 |
| Praluent PenAlirocumab | 17 | $15,120 |
| Ranolazine ErRanolazine | 78 | $13,957 |
| Metoprolol Succinate | 536 | $8,372 |
| Icosapent Ethyl | 17 | $7,482 |
| Ezetimibe | 249 | $6,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $7,765 | $1,506,271397 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $207,865 | $1,064,878132 claims |
| NovartisEntresto | $13 | $117,101105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
- Aniket RaliNashville$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.